Association between basic characteristics and immune cells in the microenvironment
| Variable | N = 240 | CD3+ T cells in the CT | CD3+ T cells in the IM | CD8+ T cells in the CT | CD8+ T cells in the IM | Immunoscore | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low | High | P | Low | High | P | Low | High | P | Low | High | P | Low | High | P | ||
| Sex | 0.894 | 1.000 | 0.355 | 0.895 | 0.326 | |||||||||||
| Male | 146 | 70 (49.3%) | 72 (50.7%) | 71 (50.0%) | 71 (50.0%) | 69 (47.3%) | 77 (52.7%) | 72 (49.3%) | 74 (50.7%) | 90 (63.4%) | 52 (36.6%) | |||||
| Female | 94 | 48 (51.1%) | 46 (48.9%) | 47 (50.0%) | 47 (50.0%) | 51 (54.3%) | 43 (45.7%) | 48 (51.1%) | 46 (48.9%) | 66 (70.2%) | 28 (29.8%) | |||||
| Age | 0.354 | 0.015 | 0.355 | 0.041 | 0.011 | |||||||||||
| < 75 | 206 | 98 (48.5%) | 104 (51.5%) | 94 (46.5%) | 108 (53.3%) | 100 (48.5%) | 106 (51.5%) | 97 (47.1%) | 109 (52.9%) | 127 (62.9%) | 75 (37.1%) | |||||
| ≥75 | 34 | 20 (58.8%) | 14 (41.2%) | 24 (70.6%) | 10 (29.4%) | 20 (58.8%) | 14 (41.2%) | 23 (67.6%) | 11 (32.3%) | 29 (85.3%) | 5 (14.7%) | |||||
| Location | 0.464 | 0.661 | 0.312 | 0.014 | 0.020 | |||||||||||
| Right | 66 | 35 (54.7%) | 29 (45.3%) | 34 (53.1%) | 30 (46.9%) | 37 (56.1%) | 29 (43.9%) | 42 (63.6%) | 24 (37.4%) | 50 (78.1%) | 14 (21.9%) | |||||
| Left | 174 | 83 (48.3%) | 89 (51.7%) | 84 (48.8%) | 88 (51.2%) | 83 (47.7%) | 91 (52.3%) | 78 (44.8%) | 96 (55.2%) | 106 (61.6%) | 66 (38.4%) | |||||
| Pathological differentiation | 1.000 | 1.000 | 0.580 | 0.580 | 0.883 | |||||||||||
| Poor | 77 | 38 (49.4%) | 39 (50.6%) | 39 (50.6%) | 38 (49.4%) | 36 (46.8%) | 41 (53.2%) | 36 (46.8%) | 41 (53.2%) | 50 (64.9%) | 27 (35.1%) | |||||
| Moderate and well | 163 | 80 (44.7%) | 79 (55.3%) | 79 (49.7%) | 80 (50.3%) | 84 (51.3%) | 79 (48.7%) | 84 (51.3%) | 79 (48.7%) | 106 (66.7%) | 53 (33.3%) | |||||
| T stage | 0.480 | 0.672 | 0.034 | 0.572 | 0.453 | |||||||||||
| T1 + T2 + T3 | 154 | 75 (49.7%) | 76 (50.3%) | 76 (50.3%) | 75 (49.7%) | 82 (51.9%) | 72 (48.1%) | 72 (46.8%) | 82 (53.2%) | 102 (67.5%) | 49 (32.5%) | |||||
| T4 | 74 | 40 (54.8%) | 33 (44.6%) | 39 (61.9%) | 34 (38.1%) | 28 (37.8%) | 46 (62.2%) | 38 (51.4%) | 36 (48.6%) | 45 (61.6%) | 28 (38.4%) | |||||
| NA | 12 | |||||||||||||||
| N stage | 0.060 | 0.080 | 0.566 | 0.774 | 0.221 | |||||||||||
| No | 73 | 31 (43.7%) | 40 (56.3%) | 32 (45.1%) | 39 (54.9%) | 32 (43.8%) | 41 (56.2%) | 32 (43.8%) | 41 (56.2%) | 42 (59.2%) | 29 (40.8%) | |||||
| N1 + N2 | 141 | 80 (57.6%) | 59 (42.4%) | 81 (58.2%) | 58 (41.8%) | 68 (48.2%) | 73 (51.8%) | 65 (46.1%) | 76 (53.9%) | 95 (68.3%) | 44 (31.7%) | |||||
| NA | 26 | |||||||||||||||
| M stage | 0.328 | 0.102 | 0.337 | 0.749 | 0.606 | |||||||||||
| M0 | 49 | 27 (57.4%) | 20 (42.6%) | 29 (61.7%) | 18 (38.3%) | 21 (42.9%) | 28 (57.1%) | 26 (53.1%) | 23 (46.9%) | 33 (70.2%) | 14 (29.88%) | |||||
| M1 | 191 | 91 (47.6%) | 98 (52.4%) | 89 (47.1%) | 100 (62.9%) | 99 (51.8%) | 92 (48.2%) | 94 (49.2%) | 97 (50.8%) | 123 (65.1%) | 66 (34.9%) | |||||
| MS | 0.429 | 1.000 | 0.682 | 1.000 | 1.000 | |||||||||||
| MSS | 158 | 73 (47.4%) | 81 (52.6%) | 73 (47.4%) | 81 (52.6%) | 80 (50.6%) | 78 (49.4%) | 75 (47.5%) | 83 (52.5%) | 97 (61.4%) | 57 (38.6%) | |||||
| MSI | 6 | 4 (66.7%) | 2 (33.3%) | 3 (50%) | 3 (50%) | 2 (33.3%) | 4 (66.7%) | 3 (33.3%) | 3 (33.3%) | 4 (66.7%) | 2 (33.3%) | |||||
| NA | 76 | |||||||||||||||
| KRAS | 0.161 | 0.470 | 0.176 | 0.262 | 0.103 | |||||||||||
| W | 48 | 15 (31.9%) | 32 (68.1%) | 15 (31.9%) | 32 (68.1%) | 21 (43.8%) | 27 (56.2%) | 21 (43.8%) | 27 (56.2%) | 22 (46.8%) | 25 (53.2%) | |||||
| M | 33 | 15 (48.4%) | 16 (51.6%) | 15 (45.5%) | 18 (64.5%) | 20 (60.6%) | 13 (39.4%) | 19 (57.6%) | 14 (42.4%) | 21 (67.7%) | 10 (32.3%) | |||||
| NA | 159 | |||||||||||||||
CT core of the tumor, IM invasive margin, NA not applicable